Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Taiyo Pharm. Expects Over \32 Billion in Sales in FY2005
June 6, 2005
- 4 Superpowers Enhance Dominance in Wholesale Industury
June 6, 2005
- Sawai: Growth in Costs Leads to Net Loss
June 6, 2005
- TOPICS 2 articles
June 6, 2005
- Nippon Chemiphar: Sales Growth of 14.8% Driven by Generics
June 6, 2005
- Once-yearly Health Exams Becoming Norm for Housewives
June 6, 2005
- SSP: Declines in Market Prices Hit Sales and Profits
June 6, 2005
- Hokuyaku Aims at Becoming General Distributor of Healthcare Products
June 6, 2005
- OTC Drugs Should Require Explanation at Time of Sale: Subcommittee
June 6, 2005
- Rohto: Record-high Sales and Profits
June 6, 2005
- Mochida: Consolidation, R&D Investment Cut into Profits
May 30, 2005
- Meiji Seika: Pharmaceutical Sales Rise 0.9% to \109,530 Mil.
May 30, 2005
- Nippon Shinyaku: Development of Urespan, Tramadol Takes Time
May 30, 2005
- Sankyo, Daiichi to Enhance Independent Marketing in Global Market
May 30, 2005
- BUSINESS NEWS IN BRIEF
May 30, 2005
- NEW PRODUCTS
May 30, 2005
- Flat Price System Is Unsuitable in Japan: Dr Okuda
May 30, 2005
- REGULATORY NEWS IN BRIEF
May 30, 2005
- Central, Local Gov't Must Cooperate Closely to Effectively Implement Amended PAL
May 30, 2005
- TPOICS
May 30, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…